公开(公告)号：US20250073219A1

公开(公告)日：2025-03-06

申请号：US18567452

申请日：2022-06-10

Applicant: NANEXA AB

Inventor： Joel HELLRUP ,  Jonas FRANSSON ,  Mårten ROOTH ,  Anders JOHANSSON ,  David WESTBERG ,  Erik LINDAHL

IPC: A61K31/454 ,  A61K9/50

Abstract: The invention relates to a plurality of coated particles containing a solid core containing one of the compounds lenalidomide and pomalidomide, or a pharmaceutically acceptable salt thereof. The core has a mean diameter of the between 0.1 pm and 50 pm. The core is a coated by a coating surrounding, enclosing and/or encapsulating the core. The coating contains a mixed oxide selected from the group consisting of iron oxide, zinc oxide, silicon oxide, titanium oxide, and aluminium oxide.

公开(公告)号：US20240277749A1

公开(公告)日：2024-08-22

申请号：US18568219

申请日：2022-06-10

Applicant: NANEXA AB

Inventor： Anders JOHANSSON ,  Mårten ROOTH ,  Erik LINDAHL ,  Joel HELLRUP ,  David WESTBERG

IPC: A61K31/706 ,  A61K9/00 ,  A61K9/10 ,  A61K9/50 ,  A61P35/00 ,  C23C16/40 ,  C23C16/455

CPC classification number: A61K31/706 ,  A61K9/0019 ,  A61K9/10 ,  A61K9/501 ,  A61K9/5073 ,  A61P35/00 ,  C23C16/407 ,  C23C16/45555

Abstract: There is provided a pharmaceutical formulation that is useful in the treatment of myelodysplastic syndrome, comprising a plurality of particles suspended in an aqueous carrier system, which particles: (a) have a weight-, number-, or volume-based mean diameter that is between amount 10 nm and about 700 μm; and (b) comprise solid cores comprising azacitidine, or a pharmaceutically-acceptable salt thereof, coated, at least in part, by a coating of inorganic material comprising mixture of: (i) zinc oxide; and (ii) one or more other metal and/or metalloid oxides, wherein the atomic ratio ((i):(ii)) is between at least 1:6 and up to and including about 6:1. Said mixed oxide coated particles are preferably synthesized via a gas phase coating technique, such as atomic layer deposition. The formulation may provide for the delayed or sustained release of azacitidine to treat myelodysplastic syndrome without a burst effect.

公开(公告)号：US20250041208A1

公开(公告)日：2025-02-06

申请号：US18717160

申请日：2022-12-08

Applicant: NANEXA AB

Inventor： Anders JOHANSSON ,  Mårten ROOTH ,  Joel HELLRUP ,  David WESTBERG

IPC: A61K9/00 ,  A61K9/50 ,  A61K31/192 ,  A61K31/196 ,  A61K31/405 ,  A61K31/407 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/5415 ,  A61K31/569 ,  A61K31/635 ,  A61K31/706

Abstract: There is provided a pharmaceutical or veterinary formulation comprising: (a) a biologically-active agent in admixture with a pharmaceutically- or veterinarily-acceptable extended-release component; (b) an antiinflammatory agent; and (c) a pharmaceutically- or veterinarily-acceptable injectable carrier. An extended-release component may also be applied to the antiinflammatory agent. The formulation may provide for the delayed or sustained release of biologically active ingredient without producing an inflammatory response after injection, and s preferably provided in the form of: (1) a plurality of particles having a weight-, number-, or volume-based mean diameter that is between about 10 nm and about 700 μm, which particles comprise solid corms comprising a biologically-active agent coated with a coating comprising at least one coating material applied by way of a gas phase deposition technique; (2) which particles are suspended in a carrier system comprising a pharmaceutically-acceptable or veterinarily-acceptable vehicle; and (3) which formulation further includes an antiinflammatory agent, which is optionally in the form of particles that are coated with a coating comprising at least one coating material applied by way of a gas phase deposition technique. Said coated particles are preferably synthesized via atomic layer deposition.

公开(公告)号：US20240277624A1

公开(公告)日：2024-08-22

申请号：US18568363

申请日：2022-06-10

Applicant: NANEXA AB

Inventor： Anders JOHANSSON ,  Mårten ROOTH ,  Erik LINDAHL ,  Joel HELLRUP ,  Jonas FRANSSON ,  David WESTBERG ,  Otto SKOLLING

IPC: A61K9/50 ,  A61K9/00 ,  A61K9/10 ,  A61K9/51 ,  A61K38/00 ,  C23C16/40 ,  C23C16/44 ,  C23C16/455

CPC classification number: A61K9/5073 ,  A61K9/0019 ,  A61K9/10 ,  A61K9/501 ,  A61K9/5115 ,  C23C16/407 ,  C23C16/4417 ,  C23C16/45555 ,  A61K38/00

Abstract: There is provided a pharmaceutical formulation that is useful in delivering a biologic active drug in a high dose, comprising a plurality of particles suspended in an aqueous carrier system, which particles: pharmaceutical formulation, comprising a plurality of particles suspended in a carrier system, which particles: (a) have a weight-, number-, or volume-based mean diameter that is between amount 10 nm and about 700 pm; and (b) comprise solid cores comprising a biologic active drug, coated, at least in part, by a coating of inorganic material, and wherein the formulation comprises a concentration of said biologic active drug of at least 10 mg/ml. Preferred biologic active drug include immunoglobulins, monoclonal antibodies, antibody mimetics, cytokines and cytokine antagonists, and human peptide hormones.